Physician profile
Pooja Singhal
NPI 1588825368
$139,885.64
in general payments reported to CMS, 2019-2025
34 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,673 · 2020: $1,006 · 2021: $8,805 · 2022: $10K · 2023: $31K · 2024: $36K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Consulting Fee: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,125 · Food and Beverage: $5,670 · Travel and Lodging: $4,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,686.66 |
| Consulting Fee | $16,415.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,125.00 |
| Food and Beverage | $5,670.30 |
| Travel and Lodging | $4,472.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46,085.64 | 2023-2025 | |
| Janssen Biotech, INC. | $32,899.39 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23,792.33 | 2019-2024 | Trulance, Xifaxan |
| Abbvie INC. | $19,279.32 | 2019-2025 | Linzess, Viberzi |
| Regeneron Healthcare Solutions, INC. | $7,953.08 | 2022-2025 | Dupixent |
| Allergan, INC. | $4,351.27 | 2019 | |
| Eli Lilly and Company | $2,187.50 | 2023 | |
| Horizon Therapeutics Plc | $800.00 | 2021 | |
| Apollo Endosurgery US INC | $690.23 | 2023 | Overstitch Endoscopic Suturing System |
| Janssen Scientific Affairs, LLC | $428.75 | 2021-2025 | Stelara, Tremfya, Simponi |
| Lilly USA, LLC | $227.84 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $212.16 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $162.72 | 2023-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $155.83 | 2020-2025 | |
| Intercept Pharmaceuticals, INC. | $98.10 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $68.09 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $60.65 | 2025 | Iqirvo |
| Novo Nordisk INC | $57.82 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Aimmune Therapeutics, INC. | $46.06 | 2024-2025 | Vowst |
| Cook Medical LLC | $41.05 | 2019-2021 | |
| Ardelyx, INC. | $34.78 | 2024-2025 | Ibsrela |
| Pfizer INC. | $29.06 | 2019-2024 | |
| Mauna Kea Technologies, INC. | $27.47 | 2025 | |
| Pharmacosmos Therapeutics INC. | $26.41 | 2025 | Monoferric |
| Celgene Corporation | $19.94 | 2024 | Zeposia |
| Celltrion USA INC. | $19.78 | 2025 | Vegzelma |
| Qol Medical, LLC | $19.28 | 2025 | Sucraid |
| Vibrant Gastro, INC. | $19.05 | 2024 | Vibrant Starter Kit |
| Merck Sharp & Dohme LLC | $16.78 | 2021 | |
| Braintree Laboratories, INC. | $16.73 | 2021 | |
| Exact Sciences Corporation | $15.54 | 2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $14.90 | 2024 | |
| Redhill Biopharma INC. | $14.43 | 2023 | Aemcolo, Talicia, Movantik |
| Currax Pharmaceuticals LLC | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Singhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.